Array BioPharma (ARRY) PT Raised to $35 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.39 +7.62%
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff raised the price target on Array BioPharma (NASDAQ: ARRY) to $35.00 (from $28.00) while maintaining a Overweight rating.
- BEACON Interim Analysis Hits, sNDA Filing in 2H:19
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Verizon (VZ) PT Lowered to $55 at TD Cowen as 'SPCX Overhang Prevails'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
